Lab-grown coronary bypass graft still working well 2 years after implantation
Cardiovascular Business12 Oct · 23:14← Topics · 12 Oct
Development ↘
Development ↘
Development ↘
Development ↘
FirstWord Pharma12 Oct · 15:44
Development ↘
The Manila Times12 Oct · 15:34
Development ↘
Yahoo Finance UK12 Oct · 15:34
As it stood that day
A lab-grown coronary bypass graft is still working well two years after implantation.
9 reports · 12 Oct
Summary · from headlines5 points
- Aficamten improves right ventricular strain and systolic pressure in oHCM.
- Aprocitentan data reinforce endothelin pathway blockade as a distinct approach across cardiometabolic disease, including obesity.
- Blood pressure control could prevent half a million deaths annually.
- Clopidogrel monotherapy was noninferior to extended DAPT but had a higher ischemic event rate.
- A lab-grown coronary bypass graft is still working well 2 years after implantation.
Latest developments6 to read first
Clopidogrel monotherapy noninferior to extended DAPT, with higher ischemic event rate: Samjin Pharm
Korea Biomedical Review12 Oct · 20:54Blood Pressure Control Could Prevent Half a Million Deaths Annually
EMJ12 Oct · 20:44Timeline 9 reports
12 Oct 20269 reports
23:001 report
22:00nothing heard
21:00nothing heard
20:002 reports
19:00nothing heard
18:00nothing heard
17:00nothing heard
16:00nothing heard
15:005 reports
14:00nothing heard
13:00nothing heard
12:00nothing heard
11:00nothing heard
10:00nothing heard
09:00nothing heard
08:00nothing heard
07:00nothing heard
06:00nothing heard
05:00nothing heard
04:00nothing heard
03:001 report
← Topics · 12 OctOne topic